A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 1, 2027

Conditions

Metastatic Castration-Resistant Prostate Cancer Patients

Interventions

DRUG

225Ac-PSMA-XT

Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.

Trial Locations (1)

RECRUITING

Cancer Hospital of Shandong First Medical University, Jinan

All Listed Sponsors

lead

Xiaorong Sun

OTHER